Merck & Co. (MRK) Stock: Headed Up On Clinical Results


Merck & Co., Inc. (NYSE: MRK) is having an incredibly strong start to the trading session this morning, and for good reason. The company released positive results from a key Phase 3 clinical trial, leading to excitement among investors and sending the stock toward the top. Today, we’ll talk about the results, what we’re seeing from MRK, and what we’ll be watching for ahead.

MRK Announces Positive Clinical Results

As mentioned above, Merck & Co. is having an incredibly strong start to the trading session this morning after releasing positive results from a key Phase 3 clinical trial. In a press release issued early this morning, the company announced that the pivotal Phase 3 KEYNOTE-189 clinical trial met its dual primary endpoint.

In the clinical trial, MRK investigated the efficacy of KEYTRUDA® in combination with pemetrexed (ALIMTA®) and cisplatin or carboplatin, for first line treatment in patients with metastatic or non-squamous non-small cell lung cancer.

According to the release, the study met its dual primary endpoints. In the release, MRK said that the treatment led to increased overall survival as well as progression free survival. MRK informed investors that full results from the clinical trial will be presented at an upcoming medical meeting as well as submitted to regulatory authorities. In a statement, Dr. Roger M. Perlmutter, President at Merck Research Laboratories had the following to say about the results:

“KEYNOTE-189 showed significant improvement in overall survival and progression-free survival for patients receiving KEYTRUDA in the first-line setting in combination with traditional chemotherapy, compared with those receiving chemotherapy alone… We are deeply grateful to the KEYNOTE-189 patients and investigators for their important contributions to this landmark study, and we look forward to presenting the data in the near future.”

How The Stock Reacted To The News

One of the first things that we learn when we start to dabble in the market is that the news causes movement. With such positive news out of Merck & Co., it’s no surprise that we’re seeing strong gains in the value of the stock this morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:43), MRK is trading at $61.91 per share after a gain of $3.25 per share or 5.54% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on MRK. In particular, we’re interested in following the story surrounding KEYTRUDA and interested in learning more about the results and the goal of submitting these results for regulatory approval. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here